- Home
- PTA vs RCUS Comparison
PTA vs RCUS Comparison
Compare PTA & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTA
- RCUS
- Stock Information
- Founded
- PTA 2020
- RCUS 2015
- Country
- PTA United States
- RCUS United States
- Employees
- PTA N/A
- RCUS N/A
- Industry
- PTA Trusts Except Educational Religious and Charitable
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- PTA Finance
- RCUS Health Care
- Exchange
- PTA Nasdaq
- RCUS Nasdaq
- Market Cap
- PTA 1.1B
- RCUS 906.4M
- IPO Year
- PTA N/A
- RCUS 2018
- Fundamental
- Price
- PTA $19.72
- RCUS $8.54
- Analyst Decision
- PTA
- RCUS Buy
- Analyst Count
- PTA 0
- RCUS 10
- Target Price
- PTA N/A
- RCUS $23.75
- AVG Volume (30 Days)
- PTA 159.2K
- RCUS 1.1M
- Earning Date
- PTA 01-01-0001
- RCUS 08-07-2025
- Dividend Yield
- PTA 8.31%
- RCUS N/A
- EPS Growth
- PTA N/A
- RCUS N/A
- EPS
- PTA N/A
- RCUS N/A
- Revenue
- PTA N/A
- RCUS $141,000,000.00
- Revenue This Year
- PTA N/A
- RCUS N/A
- Revenue Next Year
- PTA N/A
- RCUS $28.73
- P/E Ratio
- PTA N/A
- RCUS N/A
- Revenue Growth
- PTA N/A
- RCUS N/A
- 52 Week Low
- PTA $15.84
- RCUS $6.50
- 52 Week High
- PTA $19.67
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- PTA 58.15
- RCUS 42.54
- Support Level
- PTA $19.39
- RCUS $8.36
- Resistance Level
- PTA $19.86
- RCUS $8.87
- Average True Range (ATR)
- PTA 0.18
- RCUS 0.48
- MACD
- PTA -0.00
- RCUS -0.12
- Stochastic Oscillator
- PTA 72.55
- RCUS 9.09
About PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.